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ABSTRACT 
Leishmaniasis currently remains as a public health problem that it has become important, especially in 
developing countries, where the disease is endemic for most of them. Increased reports on therapeutic failu-
res by the rise of resistant strains as well as the severity of the side effects known for current treatments have 
promoted an imperative searching for novel antileishmanial agents. Such exploration has established that, in 
addition to the parasiticide effect, an immunomodulatory action could significantly contribute in therapeutics 
against leishmaniasis. The crucial observation through findings on immunomodulatory compounds is the non-
activity against promastigotes but selective parasiticide effect against macrophage-internalized amastigotes. 
However, the published examples of this type of action are few but very interesting. Therefore, the present 
work summarizes some naturally-occurring phenolic-type compounds with antileishmanial activity whose effect 
has been suggested to be exerted through an immunomodulatory mechanism.
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RESUMEN 
La leishmanioisis permanece actualmente como un problema de salud pública que ha cobrado gran rele-
vancia, sobre todo en países en vía de desarrollo, en cuya mayoría, la enfermedad es endémica. El incremento 
de reportes de fallo terapéutico por la aparición de cepas resistentes así como la severidad de los efectos 
adversos conocidos para los tratamientos actuales, han hecho imperativa la búsqueda de nuevos agentes 
antileishmaniales. En ésta búsqueda se ha establecido que, adicional al efecto parasitocida, un potencial in-
munomodulador podría contribuir significativamente en la terapéutica contra leishmaniosis. Una observación 
importante, a través de los resultados relacionados con compuestos que poseen efecto inmunomodulador, 
es la actividad parasitocida selectiva contra la forma amastigote internalizada en macrófagos, ya que la ac-
ción contra promastigotes es prácticamente nula. No obstante, en la literatura se encuentran muy pocos 
ejemplos de este tipo de acciones aunque son muy interesantes. Por lo tanto, el presente trabajo muestra 
una revisión acerca de compuestos fenólicos con potencial antileishmanial, cuyo mecanismo sugerido es la 
inmunomodulación.
Palabras	clave:	Compuestos fenólicos, Leishmania, Inmunomodulación
INTRODUCTION
Since 1988, the term leishmaniosis, instead leish-
maniasis, is the name kept by the World Association 
for the Advancement of Veterinary Parasitology (WA-
AVP) and the World Federation of Parasitologists, ac-
cording to the “Standardized Nomenclature of Animal 
Parasitic Diseases” (SNOAPAD) (Velez, 1995) in order 
to refer to the disease caused by parasites of the genus 
Leishmania. However, the term of leishmaniasis is used 
more frequently than leishmaniosis (Kassai, 2006).
Leishmaniosis is defined as a group of diseases 
with high rates of morbidity and mortality in most de-
veloping countries (WHO, 2006). The disease is cau-
sed by various species of Leishmania (Kinetoplastidae 
order). 15 species of Leishmania are well known for 
causing the illness in humans, but 13 of them exhibit 
zoonotic nature (Myler and Fasel, 2008). Leishmania 
spp. is transmitted by ca. 30 species of sandflies of 
the genus Lutzomyia in the New World, and the ge-
nus Phlebotomus in the Old World. In Colombia, L. 
panamensis and L. braziliensis are the etiological 
agents associated with more widely distributed leish-
maniosis (Saravia et al., 2002). However, a recent study 
has shown an increasing in the prevalence and distri-
bution of L. guyanensis in Colombia, reporting it as 
the etiologic agent in 94.6% cases in three zones in 
Tolima (Rodriguez-Barraquer et al., 2008), whose inci-
dence until that report was confined to the Orinoco 
and Amazon basin regions (Saravia et al., 1998).
EPIDEMIOLOGY AND CLINICAL 
ASPECTS OF LEISHMANIOSIS
Depending on the parasite species involved into 
the infection and some host factors (taking into account 
the symptoms exhibited by individuals after infection) 
leishmaniosis can be classified in three clinical syndro-
mes: cutaneous leishmaniosis (CL), mucocutaneous 
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leishmaniosis (MCL) and visceral leishmaniosis (VL). The 
last one is the most critical form of the disease, which 
can be lethal if it is untreated (Sharma and Singh, 2009).
Leishmaniosis is contemplated to be prevalent in 88 
countries, but 32 of them really consider it as endemic. 
This condition has led to an underestimation of reality 
as well as a significant public health problem (Assimi-
na et al., 2008). This disease affects more than 12 mi-
llion people worldwide. It is considered that 350 million 
people are at risk of acquiring it, and each year world-
wide are reported ca. 2 million new infections (WHO, 
2009). In Colombia, the disease is manifested as ende-
mic. In 1994, 1079 municipalities were found to have 
leishmaniosis reports, predicting a change in the inci-
dence rate within 2.00-6.66 range per 100,000 subjects 
in the rural population (King et al., 2004). Between 2003 
and 2004, 10,000 cases/year were reported, and in 2005 
the number of cases was close to 18,000 (Robledo et al., 
2006). During 2009, 15,474 cases were reported, 98.9% 
of them were found to be cutaneous leishmaniosis 
(Gutierrez-Dueñas, 2010). In 2010, the scenario did not 
change and the System of Public Health Surveillance 
(SIVIGILA, Colombia) reported 14,851 cases of leishma-
niosis (98.7% cases of cutaneous leishmaniosis) (Gutie-
rrez-Dueñas, 2011), while during 2011, 9241 cases were 
recorded (98.07 % of these were found to exhibit cuta-
neous type) (Gómez-Romero, 2012). However, it is im-
portant to note that these statistics do not consider the 
underreporting of the disease. For Colombia, 75% ca-
ses of CL were reported in Antioquia, Caquetá, Guavia-
re, Meta, Nariño, Santander, and Tolima Departments. 
Meanwhile, cases of VL were found to be concentrated 
in Bolivar, Cordoba, Sucre, and Tolima (PAHO, 2007).
TREATMENT, SIDE EFFECTS AND 
DRUG RESISTANCE
Pentavalent antimonial salts are the first-line 
treatments, which should be either intramuscularly 
or intravenously administered during an average of 
4 weeks, despite their reported high toxicity (Rodri-
gues et al., 1999). The cost of such treatment might 
be US$ 30 (generic sodium stibogluconate), US$ 120 
(meglumine antimoniate, Glucantime®), and US$ 
150 (sodium stibogluconate, Pentostam®) (Reithin-
ger and Coleman, 2007). In clinical cases where the-
rapeutic failure is reported, the second-line drugs 
for the control of leishmaniosis are highly toxic and 
their costs range from US$ 60 (Amphotericin B) and 
US$ 70 (Pentamidine, Pentacarinat ®). Although the 
liposomal amphotericin B has not been associated 
with serious adverse effects, its high cost does not 
favor the accessing for the most affected population 
(it can exceed US$ 1500 per treatment) (WHO, 2006).
In addition to the costs and adverse effects-
derived drawbacks, the problematic is increased by 
complications such as long distances for accessing 
health centers and the transportation difficulties, 
among other problems which have promoted the 
occurrence of resistant strains towards treatment 
(Pérez-Victoria et al., 2006; Rojas et al., 2006; Ribei-
ro-Gomes et al., 2004). This resistance acquisition 
(or susceptibility loss) by the parasite, along with 
the lack of therapeutic options, is reflected in do-
sage and therapy duration increases (Croft et al., 
2006), as so in the incidence of the known adver-
se effects for these formulations, even until death 
(Monzote, 2009). The resistance of antileishmanial 
chemotherapy has been reported in Southern Euro-
pe, Iran, Northeast India and South America (Rojas 
et al., 2006; Mohapatra, 2014).
All above-mentioned facts, joined to the lack of a 
vaccine, render a requirement based on the imperati-
ve searching for new chemotherapeutic alternatives. 
Understanding the pathogenesis of leishmaniosis, 
the development and implementation of immune 
based treatments could offer better opportunities 
for a successful therapy. Because of that, naturally-
occurring compounds possessing leishmanicidal 
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and immunomodulatory properties would be prefe-
rable ones (Singh and Sundar, 2014). There are many 
considerations on the important role that the regula-
tory factors from host immune status have on natural 




The role of the immune system in the develop-
ment of leishmaniasis has been well-established to 
be crucial. In this context, some individuals are natu-
rally able for controlling the infection. Thus, following 
the experimental evidence is exposed remarking the 
role of the immune system response in the patholo-
gy control.
In LC-infected individuals [who respond favo-
rably to the treatment with sodium stiboglucona-
te (Sb)] has been reported a decrease in the ex-
pression levels of IL-13 (cytokine of a Th2 profile) 
in contrast to that observed in individuals who fail 
treatment, and even, it has been seen that these in-
dividuals are characterized by the production of IL-
10 in macrophages and T cells (Maurer-Cecchini et 
al., 2009). This result is consistent with the inhibitory 
effects of IL-10 on IL-12 (Aste-Amezaga et al., 1998) 
and IFN- γ	   (D’Andrea, 1993). 
In “knock-out” C57BL/6 mice has shown a mar-
ked reduction in the effectiveness of Sb for the IFN- γ	   
gene. In addition, LV-infected patients treated with 
Sb together with recombinant IFN- γ	   replied to the 
treatment faster than those treated only with Sb 
(Sundar et al., 1995). A study involving L. peruviana-
infected patients that exhibited no response towards 
treatment with meglumine antimoniate indicates 
that when patients were treated with this pentava-
lent antimoniate therapy combined with imiquimod 
(an immunomodulatory drug), 90% patients resolved 
the infection after 6 months (Arevalo et al., 2001). 
The foregoing evidence suggests that immunomo-
dulatory activity should be an important feature in 
the search for antileishmanial agents, which would 
give advantages by enhancing the activity and/or ac-
tivate the production of soluble mediators such as 
cytokines and chemokines. These mediators, in the 
context of the disease, could be associated with pro-
tection (Ji et al., 2003).
PHENOLIC COMPOUNDS WITH 
LEISHMANICIDAL AND 
IMMUNOMODULATORY ACTIVITIES
Several reports have raised the antileishmanial 
effects by phenolics could be exerted through im-
munomodulatory mechanisms. Proanthocyanidins, 
such as catechin-(4a,8)-catechin 1 and fisetinidol-(4
The role of the immune system in the development of leishmaniasis 
has been well-established to be crucial. In this context, some 
individuals are naturally able for controlling the infection. Thus, 
following the experimental evidence is exposed remarking the 
role of the immune system response in the pathology control.
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α	  ,6)-catechin 2, obtained from Khaya senegalensis 
were evaluated for their leishmanicidal potential on 
intracellular parasites of Leishmania spp. Although 
they showed no activity on promastigotes of L. do-
novani, L. major, L. infantum and L. enriettii, these 
compounds were active against intracellular amasti-
gotes of L. donovani with EC50 ca. 3.9 µg/mL (EC50 of 
reference drug, Pentostam ®, was 7.8 µg/mL) (Kayser 
and Abreu, 2001). These results open the possibility 
to speculate that compounds: 1) could act selectively 
against amastigotes, 2) could be modified within the 
host cell and the resulted compound has the anti-
leishmanial activity, or 3) could activate the micro-
bicidal machinery of the host cell. Considering the 
latter fact, it was evaluated the tumor necrosis factor 
(TNF) production after exposure to test compounds. 
Interestingly, both compounds were associated with 
a TNF production very similar to that shown by the 
positive control (LPS + IFN-γ	  ), supporting the second 
hypothesis on immunomodulatory activity-mediated 
antileishmanial effect. These experiments have been 
extended to other structurally-related compounds. 
Within the study performed by Kolodziej et al., 2001, 
twenty-seven phenolics (some hydrolyzable tannins 
and related compounds such as ellagitannins, gallo-
tannins, C-glucosidic ellagitannins, and dehydroella-
gitannins) were evaluated for its leishmanicidal poten-
tial. None showed activity against promastigotes of 
L. donovani once more, but all phenolics were active 
against intracellular amastigotes. In addition to these 
results, other studies have recorded the trend of phe-
nolics (Kolodziej and Kiderlen, 2005; Kiderlen et al., 
2001) suggesting common action mechanisms.
In 2003, Radtke et al. published the evaluation of 
several sage phenolics against a panel of Leishmania 
parasites. They also found that these compounds ex-
hibited parasiticide activity by stimulating the immune 
response. The immunomodulatory effects were then 
evaluated on macrophage’s functions in macrophage-
like RAW 264.7, including variation of levels of TNF, in-
terleukin-6 (IL-6), and interferon (IFN), when cells were 
infected with parasites. Similarly, tested compounds 
were considered not active against promastigotes but 
caffeic acid 3, salvianolic acids K 4 and L 5, and the 
salvianolic acid I methyl ester 6 exhibited noticeable 
antileishmanial activities against intracellular amas-
tigotes (IC50 3-23 nM vs. 10-11 nM for the reference 
Pentostam) and they also showed no cytotoxicity 
on macrophages (Radtke et al., 2003). However, test 
phenolics activated Leishmania-infected host cells for 
releasing TNF ranging 22-117 U/mL and IL-6 ranging 
3-42 U/mL. In contrast, their TNF- or IL-6-inducing po-
tential in experiments with non-infected host cells was 
negligible. The results supported the promising sce-
nario that plant phenolics could be qualified for this 
mode of action in parasite control. 
On this context, extracts, coumarins and phenols obtained 
from a plant of Geraniaceae family, Pelargonium sidoides, were 
evaluated for their effects on nonspecific immune functions 
using an in vitro model for intracellular infection with s parasites 
(Kayser et al., 2001).
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On this context, extracts, coumarins and phenols 
obtained from a plant of Geraniaceae family, Pelar-
gonium sidoides, were evaluated for their effects on 
nonspecific immune functions using an in vitro mo-
del for intracellular infection with Leshmania parasi-
tes (Kayser et al., 2001). Again, test substances ex-
hibited no important activity against promastigotes 
of L. donovani. Nevertheless, extracts, gallic acid 7 
and methyl gallate 8 considerably diminished the 
amastigotes viability within host cells. These data 
also indicated that the action of the tested substan-
ces probably work across activation of leishmanicidal 
macrophage functions. This fact was concluded by 
the levels of both TNF-α	   and inorganic nitric oxides 
(iNO) in supernatants of substances-treated ma-
crophage cultures. Due to the large amounts of 7 and 
8 in P. sidoides, these metabolites were identified as 
the prominent immunomodulatory principles (Kay-
ser et al., 2001). Identical trend was recently found 
by Cabanillas et al., 2014, on evaluating various phe-
nolic compounds (diarylheptanoids 9 and flavonoids 
10) isolated from leaves and rhizomes of Renealmia 
thyrsoidea (Zingiberaceae). Test compounds exhibi-
ted activity against L. amazonensis axenic amastigo-
tes at different levels but they were also active in the 
activation of PPARγ	   nuclear receptor in macropha-
ges.  PPARγ	   is an excellent regulator of specific 
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internalization of Leishmania parasites, which is well-
known to promote the host response (Galès et al., 
2010; Chan et al., 2012). 
The immunomodulator behavior was also confir-
med by Zhu et al., 2013 through the evaluation of ex-
tracts and phenolic compounds obtained from rhizo-
mes of Osmunda japonica, which exhibited divergent 
immunomodulatory activity under in vitro conditions 
using the rat peritoneal cells. The extracts stimulated 
the NO production, and secretion of IFN-γ	  , TNF-α	   
and IL-1β	  . While minor NO enhancement was ge-
nerated by the aldehyde-type phenolics (such as 
4-hydroxybenzaldehyde 11 and 3,4-hydroxybenzal-
dehyde 12), the benzalacetone-type phenolics (such 
as 4-hydroxybenzalacetone 13 and 3,4-hydroxyben-
zalacetone 14) inhibited production of immune me-
diators including cytokines (TNF-α	  , IL-1β	  , IL-6), NO, 
and PGE2. These findings also indicated the exce-
llent potential of some phenolics on immunomodu-
latory activity. 
The phenolic lignan licarin-A 15 inhibited the 
growth Leishmania major promastigotes, by indu-
cing DNA fragmentation (Néris et al., 2013). This 
compound was more active against intracellular 
amastigotes (IC50 = 9.6 vs EC50 = 4.7 μg/mL). The 
activity against amastigotes was associated with 
immunomodulatory effects, since licarin-A-treated 
macrophage cultures exhibited a decrease in the 
interleukin (IL)-6 and IL-10 production. Other lignan, 
niranthin 16, isolated from the aerial parts of the 
plant Phyllanthus amarus, was found to be a potent 
anti-leishmanial agent by inhibition of the prolifera-
tion of Leishmania amastigotes in infected murine 
macrophages (with no significant cytotoxicity on the 
host cells) (Chowdhury et al., 2012). The effect of 16 
is considered to be conducted through a Th1-type 
immune response, which causes NO production. On 
this context, main lignans and phenolics (occurring in 
fractions of Myristica fragans) significantly inhibited, 
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IL-4 and IFN-γ	   cytokines in Con A-stimulated lym-
phocytes (Checker et al., 2008).
Flavonoids have been recognized as active princi-
ples against Leishmania amastigotes. Some of them 
include fisetin 17, 3-hydroxyflavone 18, luteolin 19,
quercetin 20 (Tasdemir et al., 2006), hispidulin 21,
santin 22 (Sülsen et al., 2007) and flavonoid dimers
(Wong et al., 2014). However, their immunomodula-
tory properties remain unknown. The evaluation of 
their effects on macrophage immune functions could 
serve as good information for synergistic antipara-
sitic compounds with the macrophages as primary 
effectors (Nahrevanian, 2006). Within this context, 
Ercil et al., 2005, evaluated 7 flavonoid glicosides 
(including kaempferol 3-O-(2’’,3’’-di-O-galloyl)-β
-D-glucopyranoside 23) isolated from Geranium
pyrenaicum, against a panel of Leishmania species 
(L. major, L. donovani and L. amazonensis) on amas-
tigote stage. These compounds also showed appre-
ciable in vitro activities (IC50 4-27 nM) in comparison 
with Pentostam (IC50 10-11 nM). The results provided 
evidence that flavonoid glycosides are able to stimu-
late defense mechanisms (through TNF, IFNγ	   and 
IL-6 levels) in Leishmania-infected RAW 264.7 cells.
In conclusion, the published results indicated 
the good antileishmanial of some phenolics. An 
important observation through findings regarding 
test compounds is the selective parasiticide activity 
against macrophage-internalized amastigote stage, 
since the action against promastigotes is practically 
ineffective. This fact is an indicative of the antileish-
manial activity by stimulating the host cell immune 
response. So far, the results therefore show a sugges-
tive value of phenolics as antileishmanial agents. 
However, the evaluations to estimate its immunomo-
dulatory potential are very scarce and insufficient, so 
further works are required to address in more detail 
the promising immunomodulatory effect of pheno-
lics and any other secondary metabolites with re-
markable antileishmanial effects.
23







































17 18 19 20
2221
UNIVERSIDAD MILITAR NUEVA GRANADA110
ISSN 1900-4699 • Volumen 10 • Número 1 • Páginas 102-114 • 2014
REFERENCES
1. Arevalo I., Ward B., Miller R., Meng T.C., Na-
jar E., Alvarez E., Matlashewski G. and Llanos-
Cuentas A. 2001. Successful treatment of drug-
resistant cutaneous leishmaniasis in humans by
use of imiquimod, an immunomodulator. Clini-
cal Infectious Disease, 33:1847-1851.
2. Assimina Z., Charilaos K. and Fotoula B. 2008. 
Leishmaniasis: an overlooked public health
concern. Health Science Journal, 2:196-205.
3. Aste-Amezaga M., Ma X., Sartori A. and Trin-
chieri G. 1998. Molecular mechanisms of the
induction of IL-12 and its inhibition by IL-10.
Journal of Immunology, 160:5936-5944.
4. Cabanillas B.J., Le Lamer A.C., Olagnier D.,
Castillo D., Arevalo J., Valadeau C., Coste A.,
Pipy B., Bourdy G., Sauvain M. and Fabre N.
2014. Leishmanicidal compounds and potent
PPAR γ	    activators from Renealmia thyrsoidea
(Ruiz & Pav.) Poepp. & Endl. Journal of Eth-
nopharmacology, 57, 18:149–155.
5. Chan M.M., Adapala N. and Chen C. 2012.
Peroxisome Proliferator-Activated Recep-
tor- γ	  -mediated polarization of macropha-
ges in Leishmania Infection. PPAR Research,
2012:1-11.
6. Checker R., Chatterjee S., Sharma D., Gupta
S., Variyar P., Sharma A. and Poduval T.B. 2008.
Immunomodulatory and radioprotective
effects of lignans derived from fresh nutmeg 
mace (Myristica fragrans) in mammalian sple-
nocytes. International Immunopharmacolo-
gy, 8:661-669.
7. Chowdhury S., Mukherjee T., Mukhopadhyay
R., Mukherjee B., Sengupta S., Chattopad-
hyay S., Jaisankar P., Roy S. and Majumder
H.K. 2012 The lignan niranthin poisons Leis-
hmania donovani topoisomerase IB and fa-
vours a Th1 immune response in mice. EMBO
Molecular Medicine, 4:1126-1143.
8. Croft SL, Sundar S and Fairlamb AH. 2006.
Drug resistance in leishmaniasis. Clinical Mi-
crobiology Reviews, 19:111-126.
9. D’Andrea A., Aste-Amezaga M., Valiante
N.M., Ma X., Kubin M. and Trinchieri G. 1993.
Interleukin 10 (IL-10) inhibits human lympho-
cyte interferon gamma-production by sup-
pressing natural killer cell stimulatory factor/
IL-12 synthesis in accessory cells. Journal of
Experimental Medicine, 178:1041-1048.
10. Ercil D., Kaloga M., Radtke O.A., Sakar M.K.,
Kiderlen A.F. and Kolodziej H. 2005. O-gallo-
yl flavonoids from Geranium pyrenaicum and
their in vitro antileishmanial activity. Turkish
Journal of Chemistry, 29:437-443.
11. Faleiro R.J., Kumar R., Hafner L.M. and En-
gwerda C.R. 2014. Immune regulation during
ACKNOWLEDGEMENT
Authors thank Universidad Militar Nueva Granada 
for the financing support. Product derived by project 
CIAS-1172 financed by Vicerrectoría de 
Investigaciones at UMNG - Validity 2013.
111
ISSN 1900-4699 • Volumen 10 • Número 1 • Páginas 102-114 • 2014
18. Kayser O. and Abreu P.M. 2001. Antileishma-
nia and Immunostimulating Activities of Two
Dimeric Proanthocyanidins From Khaya sene-
galensis. Pharmaceutical Biology, 39:284-288.
19. Kayser O., Kolodziej H. and Kiderlen A.F.
2001. Immunomodulatory principles of Pe-
largonium sidoides. Phytotherapy Research,
15:122-126.
20. Kiderlen A.F., Kayser O., Ferreira D., Kolodziej 
H. 2001. Tannins and related compounds: ki-
lling of amastigotes of Leishmania donovani
and release of nitric oxide and tumour ne-
crosis factor alpha in macrophages in vitro.
Zeitschrift für Naturforschung C, 56:444-454.
21. King R.J., Campbell-Lendrum D.H., and Da-
vies C.R. 2004. Predicting geographic varia-
tion in cutaneous leishmaniasis, Colombia.
Emerging Infectious Disease, 10:598-607.
22. Kolodziej H. and Kiderlen A.F. 2005. Anti-
leishmanial activity and immune modulatory
effects of tannins and related compounds
on Leishmania parasitised RAW 264.7 cells.
Phytochemistry, 66:2056-2071.
23. Kolodziej H., Kayser O., Kiderlen A.F., Ito
H., Hatano T., Yoshida T., Foo L.Y. 2001. An-
tileishmanial activity of hydrolyzable tan-
nins and their modulatory effects on nitric
oxide and tumour necrosis factor-alpha
Chronic Visceral Leishmaniasis. PLoS Ne-
glected Tropical Diseases, 8:e2914.
12. Galès A., Conduché A., Bernad J., Lefèvre L.,
Olagnier D., Béraud M., Martin-Blondel G.,
Linas M.D., Auwerx J., Coste A. and Pipy B.
2010. PPAR γ	    controls Dectin-1 expression
required for host antifungal defense aga-
inst Candida albicans. PLoS Pathogens, 6,
e1000714.
13. Gómez Romero S.E. 2012. Informe Epide-
miológico del Evento Leishmaniasis, Año
2011.  Instituto Nacional de Salud: Bogotá.
14. Gutiérrez Dueñas, P. 2010. Comportamiento
Epidemiológico de la Leishmaniasis en Co-
lombia. Informe Año 2009 Ajustado. Instituto
Nacional de Salud: Bogotá.
15. Gutiérrez Dueñas, P. 2011. Informe Final del
Evento de Leishmaniasis, año 2010. Instituto
Nacional de Salud: Bogotá.
16. Ji J., Sun J. and Soong L. 2003. Impaired
expression of inflammatory cytokines and
chemokines at early stages of infection with
Leishmania amazonensis. Infection and Im-
munity, 71:4278–4288.
17. Kassai T. 2006. The impact on database sear-
ching arising from inconsistency in the no-
menclature of parasitic diseases. Veterinary
Parasitology, 138:358-61.
UNIVERSIDAD MILITAR NUEVA GRANADA112
ISSN 1900-4699 • Volumen 10 • Número 1 • Páginas 102-114 • 2014
release in macrophages in vitro. Planta Me-
dica, 67:825-832.
24. Maurer-Cecchini A., Decuypere S., Chappuis 
F., Alexandrenne C., De Doncker S., Boelaert 
M., Dujardin J.C., Loutan L., Dayer J.M., Tu-
lliano G., Arevalo J., Llanos-Cuentas A. and 
Chizzolini C. 2009. Immunological determi-
nants of clinical outcome in Peruvian patients 
with tegumentary leishmaniasis treated with 
pentavalent antimonials. Infection and Im-
munity, 77:2022-2029.
25. Mohapatra S. 2014. Drug resistance in leish-
maniasis: Newer developments. Tropical Pa-
rasitology, 4:4-9
26. Monzote L. 2009. Current treatment of Leis-
hmaniasis: a review. The Open Antimicrobial 
Agents Journal, 1, 9-19.
27. Myler P.J. and N. Fasel. 2008. Leishmania: af-
ter the genome. Wymondham: Caister Aca-
demic. xiv, Pag 306.
28. Nahrevanian H. 2006. Immune effector me-
chanisms of the nitric oxide pathway in ma-
laria: cytotoxicity versus cytoprotection. 
Brazilian Journal of Infectious Diseases, 
10:283-292.
29. Néris P.L., Caldas J.P., Rodrigues Y.K., Amo-
rim F.M., Leite J.A., Rodrigues-Mascarenhas 
S., Barbosa-Filho J.M., Rodrigues L.C. and 
Oliveira M.R. 2013. Neolignan Licarin A 
presents effect against Leishmania (Leish-
mania) major associated with immunomo-
dulation in vitro. Experimental Parasitology, 
135:307-313.
30. Pan American Health Organization (PAHO), 
Health in the Americas. 2007. Scientific and 
technical publication (Washington, D.C.). 
2007, Washington, D.C.: Pan American 
Health Organization, Pan American Sanitary 
Bureau, Regional Office of the World Health 
Organization. 2 v.
31. Pérez-Victoria F.J., Sánchez-Cañete M.P., Sei-
fert K., Croft S.L., Sundar S., Castanys S. and 
Gamarro F. 2006. Mechanisms of experimen-
tal resistance of Leishmania to miltefosine: 
Implications for clinical use. Drug Resistance 
Updates, 9:26-39.
32. Radtke O.A., Foo L.Y., Lu Y., Kiderlen A.F. and 
Kolodziej H. 2003. Evaluation of sage pheno-
lics for their antileishmanial activity and mo-
dulatory effects on interleukin-6, interferon 
and tumour necrosis factor-alpha-release in 
RAW 264.7 cells. Zeitschrift für Naturfors-
chung C. 58:395-400.
33. Reithinger R and Coleman P.G. 2007. Trea-
ting cutaneous leishmaniasis patients in Ka-
bul, Afghanistan: cost-effectiveness of an 
operational program in a complex emergen-
cy setting. BMC Infectious Diseases, 7:3.
113
ISSN 1900-4699 • Volumen 10 • Número 1 • Páginas 102-114 • 2014
34. Ribeiro-Gomes F.L., Otero A.C., Gomes N.A., 
Moniz-De-Souza M.C., Cysne-Finkelstein L., 
Arnholdt A.C., Calich V.L., Coutinho S.G., Lo-
pes M.F. and DosReis G.A. 2009. Macropha-
ge interactions with neutrophils regulate 
Leishmania major infection. Journal of Im-
munology, 172:4454-4462.
35. Robledo S.M., Puerta J.A., Muñoz D.L., 
Guardo M. and Vélez I.D. 2006. Efficacy and 
tolerance of pentamidine for treatment of 
cutaneous leishmaniasis caused by por L. 
(V) panamensis in Colombia. Biomedica, 26 
Suppl 1:188-93.
36. Rodrigues M.L.O., Costa R.S., Souza C.S., 
Foss N.T. and Roselino A.M.F. 1999. Nephro-
toxicity attributed to meglumine antimoniate 
(Glucantime) in the treatment of generalized 
cutaneous leishmaniasis. Revista do Instituto 
de Medicina Tropical de São Paulo, 41:33-37.
37. Rodríguez-Barraquer I., Góngora R., Prager 
M., Pacheco R., Montero L.M., Navas A., Fe-
rro C., Miranda M.C. and Saravia N.G. 2008. 
Etiologic agent of an epidemic of cutaneous 
leishmaniasis in Tolima, Colombia. American 
Journal of Tropical Medicine and Hygiene, 
78:276-82.
38. Rojas R., Valderrama L., Valderrama M., Varo-
na M.X., Ouellette M. and Saravia N.G. 2006. 
Resistance to antimony and treatment failure 
in human Leishmania (Viannia) infection. Jour-
nal of Infectious Disease, 193:1375-1383.
39. Saravia N.G., Segura I., Holguin A.F., San-
trich C., Valderrama L. and Ocampo C. 1998. 
Epidemiologic, genetic, and clinical associa-
tions among phenotypically distinct popu-
lations of Leishmania (Viannia) in Colombia. 
American Journal of Tropical Medicine and 
Hygiene, 59: 86-94.
40. Saravia N.G., Weigle K., Navas C., Segura I., 
Valderrama L., Valencia A.Z., Escorcia B. and 
McMahon-Pratt D. 2002. Heterogeneity, geo-
graphic distribution, and pathogenicity of se-
rodemes of Leishmania viannia in Colombia. 
American Journal of Tropical Medicine and 
Hygiene, 66:738-44.
41. Sharma U. and Singh S. 2009. Immunobiolo-
gy of leishmaniasis. Indian Journal of Experi-
mental Biology. 47:412-423.
42. Singh O.P. and Sundar S. 2014. Immunothe-
rapy and targeted therapies in treatment 
of visceral leishmaniasis: current status and 
future prospects. Frontiers in Immunology, 
5:296, 1-9.
43. Sülsen V.P., Cazorla S.I., Frank F.M., Redko 
F.C., Anesini C.A., Coussio J.D., Malchiodi 
E.L., Martino V.S. and Muschietti L.V. 2007. 
Trypanocidal and leishmanicidal activities of 
flavonoids from Argentine medicinal plants. 
UNIVERSIDAD MILITAR NUEVA GRANADA114
ISSN 1900-4699 • Volumen 10 • Número 1 • Páginas 102-114 • 2014
American Journal of Tropical Medicine and 
Hygiene, 77:654-659.
44. Sundar S., Rosenkaimer F., Lesser M.L. and 
Murray H.W. 1995. Immunochemotherapy for 
a systemic intracellular infection: accelerated 
response using interferon-gamma in visceral 
leishmaniasis. Journal of Infectious Disease, 
171:992-996.
45. Tasdemir D., Kaiser M., Brun R., Yardley V., 
Schmidt T.J., Tosun F. and Rüedi P. 2006. 
Antitrypanosomal and antileishmanial acti-
vities of flavonoids and their analogues: in 
vitro, in vivo, structure-activity relationship, 
and quantitative structure-activity relations-
hip studies. Antimicrobial Agents and Che-
motherapy, 50:1352-1364.
46. Velez I.D. 1995. ¿Leishmaniosis o Leishma-
niasis?. Iatreia, 8:124-126.
47. Wong I.L., Chan K.F., Chen Y.F., Lun Z.R., Chan 
T.H. and Chow L.M. 2014. In vitro and in vivo 
efficacy of novel flavonoid dimers against cuta-
neous leishmaniasis. Antimicrobial Agents and 
Chemotherapy, 58:3379-3388. 
48. World Health Organization (WHO). Executi-
ve Board. Session, Control of leishmaniasis 
: report by the Secretariat. 2006, Geneva: 
World Health Organization. Pag 7.
49. World Health Organization (WHO). Leishma-
niasis: the global trend. Neglected tropical 




50. Zhu X.X., Li Y.J., Yang L., Zhang D., Chen Y., 
Kmonickova E., Weng X.G., Yang Q. and Zídek 
Z. 2013. Divergent immunomodulatory effects 
of extracts and phenolic compounds from the 
fern Osmunda japonica Thunb. Chinese Jour-
nal of Integrative Medicine, 19:761-770.
